IncellDx Launches BioINK PD-L1 CTC Core Kit with Lyophilized CTC Control Cells for Microfluidic Liquid Biopsies
Credit: IncellDx, Inc
Want to listen to this article for FREE?
Complete the form below to unlock access to ALL audio articles.
Read time: Less than a minute
IncellDx, a leading single cell cancer diagnostics
company has launched a complete, pre-optimized kit to identify, enumerate, and quantify the
important tumor therapeutic target PD-L1 on circulating tumor cells (CTCs). The addition of a
separate quantitative control cell cocktail, OncoTect iO Control Cells, that consists of PD-L1
positive epithelial cells; PD-L1 negative epithelial cells; and, peripheral blood mononuclear cells
(PBMCs), allows laboratories to assess linearity and lower limits of detection for CTC
enumeration with known quantities of cells in a lyophilized standard.
Dr. Bruce Patterson, CEO and founder of IncellDx said, “We are excited to launch the first of our
new BioINK reagent products for cellular liquid biopsies. BioINK™ enables highly sensitive and
specific quantification of protein or mRNA expression at a single-cell-by-cell resolution optimized
for microfluidic chips. Our proprietary fixation preserves RNA and DNA for downstream
sequencing applications following pre-identification of CTCs.”
John Stark, CEO of Celsee Inc, added, “The ability to identify and qualify at individual (or single)
cell resolution will be the future of how disease is detected and treated at an early stage. This
powerful solution, using InCellDx’s BioINK kits and Celsee’s microfluidic CTC platform, offers a
complete solution to go from sample to result that will be the first of many clinically oriented
assays that will transform single cell biology’s impact on clinical practice and immunotherapy
drug development.”
company has launched a complete, pre-optimized kit to identify, enumerate, and quantify the
important tumor therapeutic target PD-L1 on circulating tumor cells (CTCs). The addition of a
separate quantitative control cell cocktail, OncoTect iO Control Cells, that consists of PD-L1
positive epithelial cells; PD-L1 negative epithelial cells; and, peripheral blood mononuclear cells
(PBMCs), allows laboratories to assess linearity and lower limits of detection for CTC
enumeration with known quantities of cells in a lyophilized standard.
Dr. Bruce Patterson, CEO and founder of IncellDx said, “We are excited to launch the first of our
new BioINK reagent products for cellular liquid biopsies. BioINK™ enables highly sensitive and
specific quantification of protein or mRNA expression at a single-cell-by-cell resolution optimized
for microfluidic chips. Our proprietary fixation preserves RNA and DNA for downstream
sequencing applications following pre-identification of CTCs.”
John Stark, CEO of Celsee Inc, added, “The ability to identify and qualify at individual (or single)
cell resolution will be the future of how disease is detected and treated at an early stage. This
powerful solution, using InCellDx’s BioINK kits and Celsee’s microfluidic CTC platform, offers a
complete solution to go from sample to result that will be the first of many clinically oriented
assays that will transform single cell biology’s impact on clinical practice and immunotherapy
drug development.”
